SCHEMBL14377572

SCHEMBL14377572

C[C@@H](NC(=O)c1ccc(N2CC(CC#N)(n3cc(-c4ncnc5[nH]ccc45)cn3)C2)c(F)c1)C(F)(F)F

nearest known ligand 0.82

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 20/20 0.82
▸ AXL P30530 1/20 0.63
▸ JAK1 P23458 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14377481 1.00 JAK2 (0.82) JAK2AXLJAK1
SCHEMBL21799144 1.00 JAK2 (0.82) JAK2AXLJAK1
SCHEMBL14331948 0.94 JAK2 (0.80) JAK2AXLJAK1
SCHEMBL16532750 0.91 JAK2 (0.80) JAK2AXLJAK1
SCHEMBL14376756 0.91 JAK2 (0.84) JAK2AXLJAK1
SCHEMBL21412834 0.91 JAK2 (0.84) JAK2AXLJAK1
SCHEMBL29379586 0.91 JAK2 (0.84) JAK2AXLJAK1
SCHEMBL14377767 0.91 JAK2 (0.84) JAK2AXLJAK1
SCHEMBL14377480 0.91 JAK2 (0.79) JAK2AXLJAK1
SCHEMBL14377437 0.91 JAK2 (0.79) JAK2AXLJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2721028-B1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORP (US) 2015-11-04 — — EP claimed
US-20150225411-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2015-08-13 — — US claimed
US-9023840-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORPORATION (US) 2015-05-05 — — US claimed
US-20140171409-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2014-06-19 — — US claimed
US-20130018034-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2013-01-17 — — US claimed
US-11214573-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-01-04 — — US disclosed
US-11214573-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-01-04 — — US disclosed
US-20200079783-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2020-03-12 — — US disclosed
US-10513522-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORPORATION (US) 2019-12-24 — — US disclosed
US-10513522-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORPORATION (US) 2019-12-24 — — US disclosed
US-20170253598-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2017-09-07 — — US disclosed
US-20170253598-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2017-09-07 — — US disclosed
US-20140171409-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2014-06-19 — — US disclosed
US-20140171409-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2014-06-19 — — US disclosed
US-8691807-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORPORATION (US) 2014-04-08 — — US disclosed
US-8691807-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors INCYTE CORPORATION (US) 2014-04-08 — — US disclosed
US-20130018034-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2013-01-17 — — US disclosed
US-20130018034-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2013-01-17 — — US disclosed
US-20130018034-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2013-01-17 — — US disclosed
WO-2012177606-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2012-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10513522-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors JAK1, JAK3, JAK2 JAK2 3/4885AXL 526/4885JAK1 1/4885
US-20130018034-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 JAK2 3/4885AXL 526/4885JAK1 1/4885
US-11214573-B2 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors JAK1, JAK3, JAK2 JAK2 3/4885AXL 526/4885JAK1 1/4885
US-20140171409-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 JAK2 3/4885AXL 526/4885JAK1 1/4885
US-20170253598-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 JAK2 3/4885AXL 526/4885JAK1 1/4885
US-20200079783-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 JAK2 3/4885AXL 526/4885JAK1 1/4885
US-20150225411-A1 AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 JAK2 3/4885AXL 526/4885JAK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback